Introduction
============

*Acinetobacter baumannii* is a significant infectious microbial factor in hospitalized patients throughout the world, and the associated mortality and morbidity have been increasing ([@b1-etm-0-0-7927]). It is an opportunistic bacterial pathogen, with a major involvement in sepsis, pneumonia, urinary tract infection and primary bacteremia. According to the US National Healthcare Safety Network surveillance data for 2009--2010, *A. baumannii* caused 1.8% of all healthcare-associated infections ([@b2-etm-0-0-7927]). Isolates of the strains of *A. baumannii* with extensive multi-drug resistance (MDR) have raised significant concern. Carbapenem- and colistin-resistant *A. baumannii* strains are considered an emerging, serious public health problem ([@b3-etm-0-0-7927]). The emergence of carbapenem resistance genes and β-lactamase gene in *A. baumannii* has arisen as a significant public health concern ([@b4-etm-0-0-7927]). The carbapenem-resistant attribute of *A. baumannii* is principally associated with OXA-type β-lactamases, particularly OXA-23. The development of antibiotic resistance of this species has been associated with the emergence of New Delhi metallo-β-lactamase 1 (NDM-1), the potent carbapenem resistance gene ([@b5-etm-0-0-7927]). Several distinct species of *Enterobacteriaceae* have been reported to harbour NDM-1. Studies have reported on *A. baumannii* with NDM-1 from environmental and clinical isolates in various countries ([@b6-etm-0-0-7927],[@b7-etm-0-0-7927]).

Meropenem is a carbapenem antibiotic with the ability to bind to penicillin-binding proteins and inhibit β-lactamase with the broadest spectrum of activity among β-lactam antibiotics ([@b8-etm-0-0-7927]). Vancomycin is a glycopeptide antibiotic that is an inhibitor of bacterial peptidoglycan synthesis ([@b9-etm-0-0-7927]). Colistin is a cationic polypeptide antibiotic with the ability to increase the permeability of the cell membrane, ultimately leading to bacterial death. Tazobactam and sulbactam only inhibit selected class A enzymes, excluding *Klebsiella pneumoniae* carbapenemase (KPC)-type carbapenemases, generally have a minimal effect on AmpC β-lactamases, and have been reported to exhibit the intrinsic anti-bacterial activity on strains of *Acinetobacter* at concentrations attainable in the human body (5.5--51 and \~40 mg/l, respectively) ([@b10-etm-0-0-7927]--[@b12-etm-0-0-7927]).

In another study, the reintroduction of colistin, which is the only remaining active microbial factor with an *in vitro* anti-bacterial effect on MDR Gram-negative bacteria, has been reported for treating carbapenem-resistant strains of *A. baumannii* ([@b13-etm-0-0-7927]). The colistin resistance of *A. baumannii* strains is well-documented ([@b3-etm-0-0-7927]), and it is based on the following two mechanisms: Modification of lipid A and lipopolysaccharide loss ([@b14-etm-0-0-7927],[@b15-etm-0-0-7927]). Vancomycin is an inhibitor of bacterial peptidoglycan synthesis, which lacks activity against Gram-negative bacteria due to its large size and hydrophobicity. When colistin was combined with vancomycin, a molecule that should ordinarily have no effect on Gram-negative organisms, due to the relative impermeability of the outer membrane to such a large hydrophobic molecule, a synergistic effect is achieved, and this treatment may become the most common therapy for MDR *A. baumannii* infections in the future ([@b16-etm-0-0-7927]).

The present study explored the genetic environment of clinical MDR strains of *A. baumannii* carrying the NDM-1 gene, and determined the *in vitro* effects of meropenem in conjunction with colistin, ampicillin-sulbactam, tazobactam as well as vancomycin.

Materials and methods
=====================

### Bacterial strains and growth conditions

Strains of *A. baumannii* (n=264) were selected from the pool of clinical isolates from the North of China that were obtained between June 2000 and August 2015. The isolates were obtained from urine (n=55), blood (n=73), bronchoalveolar lavage fluid (n=72), abdominal samples (n=18), cerebrospinal fluid (CSF) (n=29), catheter tips (n=8) and stool specimens (n=9) at hospitals including the Second Affiliated Hospital of Henan University of Science and Technology (Luoyang, China), the Beijing ChuiYangLiu Hospital affiliated to Tsinghua University (Beijing, China), Hongqi Hospital of Mudanjiang Medical College (Mudanjiang, China) and the Second Affiliated Hospital of Mudanjiang Medical College (Mudanjiang, China). Standard strains of *A. baumannii* (American Type Culture Collection (ATCC) 19606; ATCC, Manassas, VA, USA) and *Escherichia coli* (ATCC 25922; ATCC) were used in each run as the control. *A. baumannii* strains were identified by the use of a Vitek 2 system (BioMérieux Inc., Marcy-l′Étoile, France). The isolates were stored at −80°C. Mueller-Hinton broth II (MHB II; Difco Laboratories; BD Biosciences, San Jose, CA, USA) was used for all *in vitro* experiments. The strains were grown at 37°C with 5% CO~2~.

### Determination of anti-microbial susceptibility

Antibiotic susceptibility was measured with the use of the standard disc diffusion process suggested by the Clinical and Laboratory Standards Institute (CLSI) guidelines by broth microdilution and E-test (cat. nos. 537300, 501800, 533500, 501300, 501600, 506710, 513800, 526000, 523600, 525508, 522000, 503500 and 521400; AB Biodisk; BioMérieux Inc.) ([@b17-etm-0-0-7927]). A total of 14 antibiotics were tested, including ampicillin-sulbactam, trimethoprim-sulfamethoxazole, aminoglycoside antibiotic amikacin, macrolide antibiotic azithromycin, β-lactam antibiotic aztreonam, β-lactamase inhibitor tazobactam, cephalosporin antibiotics ceftazidime and cephalothin, rifampin and tigecycline, carbapenem antibiotic meropenem and colistin, and the glycopeptide antibiotics teicoplanin and vancomycin (Bio-Rad, Laboratories, Inc., Hercules, CA, USA). These antibiotics are of different classes and have different killing mechanisms on the bacteria. The E-test technique was used to determine the minimum inhibitory concentrations (MICs) of meropenem. The results were interpreted according to the CLSI guidelines from 2015 ([@b18-etm-0-0-7927]).

### Detection of antibiotic resistance genes

With reference to previous studies, a multiplex polymerase chain reaction (PCR)-reverse line blot assay was employed in the present study for detecting various clinically significant antibiotic resistance genes \[NDM-1, VIM, IMP, SHV-5/12-like, VEB, KPC, OXA-10-like, CTX-M, TEM, OXA-23-like, OXA-30-like, DHA, CMY-2-like, armA, rmtC, aac(3)-IIc, aadB, aacC1, aac(6′)-Ib-cr, qnrA, qnrB and qnrS\] ([@b17-etm-0-0-7927],[@b19-etm-0-0-7927]). The primers are provided in [Table I](#tI-etm-0-0-7927){ref-type="table"}. PCR and genome walking were used to extend uncharacterized flanking regions of the NDM-1 gene ([@b20-etm-0-0-7927]--[@b23-etm-0-0-7927]).

### Molecular typing by multilocus sequence typing (MLST)

Strains were identified at the species level using the Vitek 2 system (BioMérieux) and then confirmed by 16S ribosomal DNA sequencing. Housekeeping genes (cpn60, gltA, gdhB, gpi, gyrB, recA and rpoD) were also detected by MLST and then sequenced ([@b24-etm-0-0-7927]). Tools obtained from the *A. baumannii* MLST database (<http://pubmlst.org/abaumannii/>) were employed to assign the isolates to sequence types (STs).

Phenotypic detection of NDM-1 production
----------------------------------------

### Modified Hodge test

In the present study, the modified Hodge test for *Enterobacteriaceae* was performed according to the CLSI guidelines from 2015 ([@b18-etm-0-0-7927]). In brief, a 0.5 McFarland standard *E. coli* ATCC 25922 suspension was diluted at 1:10 and then spread onto Mueller-Hinton agar plates. Ertapenem (10 µg), imipenem (10 µg), and meropenem (10 µg) disks were placed. Subsequently, with the use of a sterile wire loop, 3--5 colonies of the isolated strain were inoculated in a straight line out from the rim on the same plate. *K. pneumoniae* ATCC 1705 was used as the Mueller-Hinton Test (MHT)-positive quality control (QC) organism and *K. pneumoniae* ATCC 1706 as the MHT-negative QC organism. The plates were then incubated for 16 to 20 h at a temperature of 37°C in ambient air ([@b25-etm-0-0-7927]). Those isolates with an intermediate or susceptible zone, i.e. 16--21 mm on disc diffusion, were considered to be positive for carbapenemase production.

### Combined disk test (CDT) with EDTA

To detect NDM-1, the EDTA-CDT was performed using disks with meropenem (10 µg) and imipenem (10 µg), utilizing 750 µg EDTA ([@b26-etm-0-0-7927]--[@b28-etm-0-0-7927]). The inhibition zone on the disk containing one antibiotic was compared with that on the disk with the combination of one antibiotic and EDTA. If the increase in the inhibition zone on the combined disk was \>7 mm compared with that on the disc with imipenem alone, the strain was considered metallo-beta-lactamase-positive.

### Checkerboard assay

The checkerboard tests aimed to validate the presence of synergism among anti-microbial agents at fixed concentrations. Checkerboard analysis was performed with colistin, vancomycin and β-lactamase inhibitors combined with meropenem. The checkerboard assay was used to determine antibiotic interactions, as previously described ([@b29-etm-0-0-7927],[@b30-etm-0-0-7927]). The anti-microbials or β-lactamase inhibitors were applied in cation-adjusted Mueller-Hinton II broth (MHB II) at the following concentrations: Meropenem, 1--512 mg/l; ampicillin-sulbactam, 1/0.5--512/256 mg/l, tazobactam, 0.25--512 mg/l; and colistin, 0.124--32 mg/l. MHB II was filled into each well of 96-well, round-bottomed microtiter plates. The essential volume of drug solution at a concentration corresponding to the desired final concentration was then added to the wells. The final inoculum concentration of the *A. baumannii* was \~5×10^5^ CFU/ml in a total volume of 200 µl. The plates were incubated at a temperature of 37°C for 48 h under aerobic conditions.

The turbidity of each well was assumed to represent microbiological growth. To define the interaction between anti-microbials, the fractional inhibitory concentration index (FICI) was employed, which was rated as follows: FICI≤0.5, synergism; 0.5\<FICI≤4, indifference; FICI\>4, antagonism ([@b31-etm-0-0-7927]).

### Time-kill curve analysis

*A. baumannii* strain was diluted to \~5×10^5^ CFU/ml with Mueller-Hinton broth. The drug concentrations of meropenem and colistin were adjusted to the 1×MIC or 0.5×MIC in the time-kill curve analysis. The Erlenmeyer flask was incubated at 37°C under aerobic conditions. The number of bacteria was determined at 0, 2, 4, 6, 8, 12, 24, 30, 36 and 48 h ([@b32-etm-0-0-7927]).

### Statistical analysis

Values are expressed as the mean ± standard deviation. Statistical analysis was performed using GraphPad prism version 5.01 (GraphPad Inc., La Jolla, CA, USA). Two-way analysis of variance with Bonferroni\'s post-hoc tests was used to compare each group of antibiotics to the control group at the same time.

Results
=======

### In vitro susceptibility and genetic characterization of isolates

In the present study, five NDM-1-containing *A. baumannii* strains were identified among 264 isolates by PCR screening. Of these isolates, 3 were from blood specimens, one was from a cerebrospinal fluid sample and one was a urine isolate. All of the strains were resistant to the test antibiotics ([Table II](#tII-etm-0-0-7927){ref-type="table"}). By MLST, two strains were identified to be of ST357, while the remaining three strains were of ST191. Different genetic elements can influence the transmission of NDM-1 ([Fig. 1](#f1-etm-0-0-7927){ref-type="fig"}). The ISAba125 element was present upstream of the NDM-1 gene in the five strains and may facilitate the rapid dissemination of the NDM-1 gene. As the NDM-1 *A. baumannii* strains were resistant to numerous antibiotics and carried a number of resistance genes, the characteristics of these strains were next studied.

### Phenotypic detection of NDM-1 production

The modified Hodge test was employed to detect carbapenemase production in the five isolates. The CDT in conjunction with EDTA revealed that the activity of NDM-1 was inhibited by EDTA.

### Checkerboard assay

A synergistic interaction was identified for colistin-meropenem in four strains, for meropenem-ampicillin-sulbactam in two strains, for meropenem-vancomycin in two strains, as well as for meropenem-tazobactam in two strains ([Table III](#tIII-etm-0-0-7927){ref-type="table"}). No antagonistic activity was detected for any of the combinations.

### Activities of meropenem, colistin and their combination in a time-kill curve analysis

The second strain and the fourth strain harbored the NDM-1 and CTX-M genes. A synergistic interaction of colistin and meropenem was detected in these two strains, and the strains were therefore selected to study the inhibitory activities of the combination of colistin and meropenem in a time-kill curve analysis. When each strain was incubated with meropenem at a concentration of 0.5×MIC (16 mg/l), the bacterial growth was transiently inhibited but then regrew again ([Fig. 2](#f2-etm-0-0-7927){ref-type="fig"}). Colistin at concentrations of 0.5×MIC (4 mg/l) and 1×MIC (8 mg/l) did not inhibit the growth of the two strains, although the concentration of 1×MIC (8 mg/l) had a transient inhibitory activity lasting for \<6 h. The combination of meropenem and colistin at a concentration of 0.5×MIC had an inhibitory effect on the strains that lasted for longer than either antibiotic alone (up to 24 h). However, a sustained synergistic inhibitory activity lasting for \>48 h was obtained with meropenem at a concentration of 0.5×MIC combined with colistin at a concentration of 1×MIC. After 48 h of cultivation, the bacterial quantity of the second strain was significantly affected in the presence of meropenem and colistin combined at a concentration of 0.5×MIC, as well as meropenem at 0.5×MIC combined with colistin at 1×MIC compared with that in the control group (P\<0.001 for either; [Fig. 2C](#f2-etm-0-0-7927){ref-type="fig"}). Furthermore, for the fourth strain, the number of cells was also significantly affected by the combination of meropenem and colistin at a concentration of 0.5×MIC and by the combination of meropenem at 0.5×MIC and colistin at 1×MIC (P\<0.001 for either; [Fig. 2D](#f2-etm-0-0-7927){ref-type="fig"}).

Discussion
==========

*A. baumannii*, a significant nosocomial pathogen, particularly in intensive care units, is a major public health concern. Certain strains of this bacterium are resistant to a range of anti-microbial factors, including β-lactams, aminoglycosides, carbapenems and fluoroquinolones ([@b33-etm-0-0-7927]). The concern over this organism is mainly attributed to the rising MDR, encompassing colistin and carbapenems. NDM-1 is a β-lactamase belonging to an Ambler class B, and resistance to all β-lactams with the exception of aztreonam is conferred by this organism ([@b34-etm-0-0-7927]). NDM-1-positive *Acinetobacter spp*, with *A. baumanii, A. pittii* as well as *A. lwoffii* included, have been reported in China ([@b35-etm-0-0-7927],[@b36-etm-0-0-7927]). Studies have also reported NDM-1 in *A. baumannii* isolated in certain other countries from 2010 onwards, and it was hypothesized that NDM-1 associated with the Tn125 transposon originates from the *A. baumannii* strain in a specific area of North Africa prior to the transfer to *Enterobacteriaceae* ([@b37-etm-0-0-7927]). Tn125 may be the major vehicle for the dissemination of NDM-1 genes in strains of *A. baumannii*. ISAba125 is present upstream of the NDM-1 gene and is also associated with the horizontal transfer of NDM-1 in *A. baumannii* ([@b38-etm-0-0-7927]). In the present study, ISAba125 was located upstream of NDM-1 in the five strains. The genes encoding the GroEL and GroES chaperonin proteins were identified downstream of NDM-1 in the five strains. These genes may be associated with the transfer of NDM-1.

Due to the emerging resistance and insufficient efficacy of the remaining monotherapy options, antibiotic combination therapy is increasingly used ([@b39-etm-0-0-7927]). However, clinical evidence for specific antibiotic combinations is lacking. Therefore, *in vitro* data derived from checkerboard or time-kill experiments are used to support the choice of treatment ([@b40-etm-0-0-7927]). Drug combinations have been used to defeat extensively MDR *A. baumannii* isolates, and the efficacy of combinations amongst the drugs has also been demonstrated *in vitro* ([@b41-etm-0-0-7927]). A previous study has demonstrated the synergy of imipenem and amikacin in a mouse model, but there was no improvement on imipenem monotherapy ([@b42-etm-0-0-7927]). Combinations of antimicrobial agents including rifampicin have been reported to have synergistic effects on MDR *A. baumannii* isolates. In a clinical study, imipenem + rifampicin combination therapy led to rifampicin resistance in the treatment of infections with carbapenem-resistant *A. baumannii* strains ([@b43-etm-0-0-7927]). In spite of good efficacy against infections of *A. baumannii*, colistin treatment has been abandoned due to its toxicity, whereas its use is now re-emerging ([@b44-etm-0-0-7927]). Despite the lack of sufficient evidence for the clinical benefit, the combination of colistin with rifampin has appeared to be one of the most commonly researched combinations *in vitro* ([@b3-etm-0-0-7927]). Another study demonstrated the effectiveness of sulbactam in the treatment of infections with carbapenem-resistant *A. baumannii* strains ([@b45-etm-0-0-7927]). The synergistic effect of sulbactam in conjunction with colistin on colistin-resistant *A. baumannii* strains has been reported ([@b46-etm-0-0-7927]). Normally, due to the relative impermeability of the outer membrane to such large hydrophobic molecules, vancomycin should exert no effect against Gram-negative organisms. However, colistin combined with vancomycin exhibited synergy ([@b44-etm-0-0-7927]). Meropenem combined with sulbactam exerted a more potent anti-microbial effect on certain *A. baumannii* strains than meropenem or sulbactam alone ([@b32-etm-0-0-7927]). In the present study, meropenem in combination with colistin, ampicillin-sulbactam, tazobactam and vancomycin exhibited synergistic effects against most strains harboring the NDM-1 gene in the checkerboard test. Meropenem with colistin was mostly effective against the MDR isolates of *A. baumannii*, which had a synergistic effect of 80% against *A. baumannii*, while other groups only had a synergistic effect of 40%. In the time-kill curve analysis, the combination of meropenem (0.5×MIC) and colistin (1×MIC) had a sustained synergistic bactericidal effect lasting for at least 48 h. Further clinical studies on the combination of the two drugs are required for delineating its clinical significance.

In conclusion, the present study indicated that meropenem plus colistin, ampicillin-sulbactam, tazobactam and vancomycin were effective against certain MDR strains of *A. baumannii* carrying the NDM-1 gene *in vitro*, and the combination therapy should be assessed in future *in vivo* pharmacological and toxicological studies.
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###### 

Primers used for the amplification of selected carbapenemase genes.

  Gene              Primer name       Sequence                             Fragment size (bp)
  ----------------- ----------------- ------------------------------------ --------------------
  NDM-1             NDM-1 F           5′-ATGGAATTGCCCAATATTATGCACCCGG-3′   813
                    NDM-1 R           5′-TCAGCGCAGCTTGTCGGCCATG-3′         
  VIM-1 and −2      VIM F             GATGGTGTTTGGTCGCATA                  390
                    VIM R             CGAATGCGCAGCACCAG                    
  IMP               MultiIMP F        5′-TTGACACTCCATTTACDG-3′             139
                    MultiIMP R        5′-GATYGAGAATTAAGCCACYCT-3′          
  SHV-5/12-like     SHV F             5′-GCCTTTATCGGCCCTCACTCAAG-3′        897
                    SHV R             5′-TTAGCGTTGCCAGTGCTCGATCA-3′        
  VEB               VEB F             CATTTCCCGATGCAAAGCGT                 648
                    VEB R             CGAAGTTTCTTTGGACTCTG                 
  KPC               KPC F             5′-TGTCACTGTATCGCCGTC-3′             1010
                    KPC R             5′-CTCAGTGCTCTACAGAAAACC-3′          
  OXA-10-like       OXA-10 F          5′-CCACCAAGAAGGTGCCATGA-3′           835
                    OXA-10 R          5′-GCGACCTTGAGCGACTTGTT-3′           
  CTX-M             CTX-M Gp1 F       5′-TTAGGAARTGTGCCGCTGYA-3′           688
                    CTX-M Gp1 R       5′-CGATATCGTTGGTGGTRCCAT-3′          
  TEM               TEM F             5′-ATAAAATTCTTGAAGACGAAA-3′          1079
                    TEM R             5′-GACAGTTAGCAATGCTTAATCA-3′         
  OXA-23-like       OXA-23 F          5′-GATGTGTCATAGTATTCGTCG-3′          1067
                    OXA-23 R          5′-TCACAACAACTAAAAGCACTG-3′          
  OXA-30-like       OXA-30 F          5′-GGCACCAGATTCAACTTTCAAG-3′         564
                    OXA-30 R          5′-GACCCCAAGTTTCCTGTAAGTG-3′         
  DHA               DHA F             5′-AACTTTCACAGGTGTGCTGGGT-3′         405
                    DHA R             5′-CCGTACGCATACTGGCTTTGC-3′          
  CMY-2-like        CMY-2 F           5′-GCTGAGAGCTCATGATGAAAAAATCG-3′     1146
                    CMY-2 R           5′-GGTACGGATCCTTATTGCAGC-3′          
  *armA*            armA F            5′-ATTCTGCCTATCCTAATTGG-3′           315
                    armA R            5′-ACCTATACTTTATCGTCGTC-3′           
  *rmtC*            rmtC F            5′-CGAAGAAGTAACAGCCAAAG-3′           711
                    rmtC R            5′-ATCCCAACATCTCTCCCACT-3′           
  *aac(3)-IIc*      aac(3)-IIc F      5′-ACGCGGAAGGCAATAACGGA-3′           854
                    aac(3)-IIc R      5′-TAACCTGAAGGCTCGCAAGA-3′           
  *aac(6′)-Ib-cr*   aac(6′)-Ib-cr F   5′-TTGCGATGCTCTATGAGTGGCTA-3′        482
                    aac(6′)-Ib-cr R   5′-CTCGAATGCCTGGCGTGTTT-3′           
  *aadB*                              5′-AACGCAGGTCACATTGATACA-3′          266
                                      5′-ACCAAGCAGGTTCGCAGTC-3′            
  *aacC1*           aacC1 F           5′-CACCTACTCCCAACATCAGC-3′           329
                    aacC1 R           5′-CTTCCCGTATGCCCAACT-3′             
  *qnrA*            qnrA F            5′-ATTTCTCACGCCAGGATTTG-3′           
                    qnrA R            5′-GATCGGCAAAGGTTAGGTCA-3′           516
  *qnrB*            qnrB F            5′-ACGATGCCTGGTAGTTGTCC-3′           469
                    qnrB R            5′-GATCGTGAAAGCCAGAAAGG-3′           
  *qnrS*            qnrS F            5′-ACGACATTCGTCAACTGCAA-3′           417
                    qnrS R            5′-TAAATTGGCACCCTGTAGGC-3′           

F, forward; R, reverse; NDM-1, New Delhi metallo-β-lactamase 1; *bla*, β-lactamase.

###### 

MIC values of NDM-1-producing and colistin-resistant *A. baumannii* strains.

                                                                                          MIC (µg/ml)                                                                             
  --- ----------------------------------------------------- ------- --------------------- ------------- --- -------- ---- ----- ----- ----- ----- ----- --- --------- ----- ----- ------
  1   *blaNDM-1, VIM-16, blaKPC, aadB, blaOXA-23*           ST191   Blood                 8             8   64/32    8    256   128   64    64    128   4   64/1216   64    128   1024
  2   *blaNDM-1, blaCTX-M, aacC1*                           ST191   Blood                 128           8   32/16    8    128   64    64    64    32    4   32/1216   32    128   512
  3   *blaNDM-1, blaCMY-2-like, aadB*,                      ST357   Cerebrospinal fluid   32            4   128/64   4    32    64    128   32    64    8   64/608    32    256   512
  4   *blaNDM-1, blaOXA-23, blaCTX-M, aac(6′)-Ib-cr*        ST357   Urine                 32            8   64/32    16   32    32    32    128   32    8   32/608    64    512   256
  5   *blaNDM-1, blaOXA-10, blaCMY-2-like, aac(6′)-Ib-cr*   ST191   Cerebrospinal fluid   16            8   32/16    32   128   64    32    64    128   4   128/608   128   256   1024

MIC, minimum inhibitory concentration; CST, colistin; SAM, ampicillin-sulbactam; TGC, tigecycline; AMK, amikacin; AZM, azithromycin; ATM, aztreonam; CAZ, ceftazidime; MEM, meropenem; RIF, rifampin; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin; TEC, teicoplanin; CEP, cephalothin; TZP, tazobactam; NDM-1, New Delhi metallo-β-lactamase 1; ST, sequence type.

###### 

Results of the checkerboard synergy test of *A. baumannii* harboring New Delhi metallo-β-lactamase 1.

                              Meropenem + vancomycin   Meropenem + ampicillin-sulbactam   Meropenem + tazobactam   Meropenem + colistin                                  
  --------------------------- ------------------------ ---------------------------------- ------------------------ ---------------------- ------- -------------- ------- --------------
  *A. baumannii* ATCC 19606   0.25                     Synergism                          0.5                      Synergism              0.37    Synergism      0.26    Synergism
  1                           0.310                    Synergism                          0.265                    Synergism              1.25    Indifference   1.25    Indifference
  2                           0.750                    Indifference                       0.532                    Indifference           0.281   Synergism      0.281   Synergism
  3                           0.562                    Indifference                       1.301                    Indifference           0.375   Synergism      0.375   Synergism
  4                           0.257                    Synergism                          1.057                    Indifference           1.642   Indifference   0.281   Synergism
  5                           0.255                    Indifference                       0.124                    Synergism              2.000   Indifference   0.140   Synergism

FICI, fractional inhibitory concentration index; ATCC, American Type Culture Collection.
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